Our experience with propranolol for infantile hemangioma

Area of Science:

• Pediatric Dermatology
• Vascular Biology
• Pharmacology

Background:

• Infantile hemangioma (IH) is the most common benign vascular tumor in children.
• Propranolol is the first-line treatment for severe IH.
• Optimal timing for initiating and discontinuing propranolol remains debated.

Purpose of the Study:

• To investigate the impact of early propranolol treatment on infantile hemangioma regression.
• To identify factors influencing treatment duration and recurrence rates.
• To evaluate the optimal timing for propranolol dosage reduction.

Main Methods:

• A retrospective study of 90 patients with infantile hemangioma treated with propranolol between 2016 and 2019.
• Patients were categorized into complete and partial regression groups based on treatment outcomes.
• Color Doppler ultrasound was used to assess hemangioma characteristics.

Main Results:

• The complete regression group had a significantly shorter initial treatment period (4.3 months) compared to the partial regression group (5.2 months).
• Treatment duration was longer in the partial regression group (32.9 months) versus the complete regression group (23.4 months).
• Facial hemangiomas, particularly periocular, showed a higher proportion in the regression group.

Conclusions:

• Early initiation of propranolol treatment for infantile hemangioma is associated with faster regression.
• Patient age and tumor regression percentage are key factors in determining propranolol dosage reduction.
• Periocular hemangiomas may have a better prognosis, warranting further investigation.